23andMe Investor Presentation Deck
Investing in Future Growth in a Fiscally
Responsible Manner
1 Investing in future growth potential. For those business segments
expected to drive future growth, including the new genetic health services
and our therapeutics business, we plan to focus on the most strategically
and financially valuable options and invest appropriately in each.
2 Employing a conservative approach to planning. Recognizing the current
uncertainties in the economy and financial markets, we are prioritizing the
minimization of Adjusted EBITDA deficit rather than maximizing top-line
growth in our Consumer business (PGS and telehealth).
3
Solid cash position. Cash of $479 million¹ supports 23andMe's plans for
significant investment in Therapeutics portfolio and strategic initiatives.
¹As of June 30, 2022.
Copyright © 2022 23and Me, Inc.
23andMe
49View entire presentation